HLN:NYE-Haleon plc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 10.04

Change

-0.10 (-0.99)%

Market Cap

USD 46.89B

Volume

6.44M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict
Created with Highstock 5.0.6

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
HLN VTI
  • VTI
Relative Returns (From:    To: 2025-03-25 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

-1.91 (-1.16%)

USD 72.21B
TAK Takeda Pharmaceutical Co Ltd A..

-0.09 (-0.59%)

USD 47.88B
RDY Dr. Reddy’s Laboratories Ltd..

-0.07 (-0.53%)

USD 10.62B
ELAN Elanco Animal Health

-0.40 (-3.70%)

USD 5.51B
AMRX Amneal Pharmaceuticals, Inc. C..

+0.02 (+0.18%)

USD 4.11B
BHC Bausch Health Companies Inc

-0.27 (-4.00%)

USD 2.64B
CPHI China Pharma Holdings Inc

-0.02 (-5.37%)

USD 3.69M
YCBD cbdMD Inc

-0.02 (-7.69%)

USD 1.96M
APUS Apimeds Pharmaceuticals US, In..

N/A

N/A
EBS Emergent Biosolutions Inc

-0.26 (-5.28%)

N/A

ETFs Containing HLN

C1U:PA Amundi FTSE 100 UCITS 4.49 % 0.00 %

-5.80 (0.18%)

USD 0.04B
CUIK:XETRA 4.38 % 0.00 %

N/A

N/A
UKSRE:SW UBS (Irl) ETF plc - MSCI .. 3.61 % 0.00 %

N/A

USD 0.10B
STSX:SW SPDR® MSCI Europe Consum.. 3.55 % 0.00 %

+2.20 (+0.18%)

USD 0.14B
UKSR:SW UBS (Irl) ETF plc - MSCI .. 3.41 % 0.00 %

-0.02 (0.18%)

USD 0.72B
UKSRT:SW UBS (Irl) ETF plc - MSCI .. 3.41 % 0.00 %

+0.02 (+0.18%)

USD 0.01B
CSPE:LSE SPDR® MSCI Europe Consum.. 2.44 % 0.00 %

+2.14 (+0.18%)

N/A
UKSR:LSE UBS (Irl) ETF plc - MSCI .. 0.00 % 0.00 %

+0.30 (+0.18%)

USD 0.73B
STW:PA SPDR® MSCI Europe Health.. 0.00 % 0.00 %

+0.90 (+0.18%)

USD 0.72B
DXSK:F Xtrackers - Stoxx Europe .. 0.00 % 0.00 %

+1.36 (+0.18%)

N/A
EXV4:F 0.00 % 0.00 %

N/A

N/A
SPYC:F SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

N/A

N/A
DXSE:XETRA Xtrackers - Stoxx Europe .. 0.00 % 0.00 %

+0.85 (+0.18%)

USD 0.14B
EXV4:XETRA iShares STOXX Europe 600 .. 0.00 % 0.00 %

+0.36 (+0.18%)

USD 0.70B
SPYC:XETRA SPDR® MSCI Europe Consum.. 0.00 % 0.00 %

+1.65 (+0.18%)

N/A
FT1K:LSE Amundi MSCI UK IMI SRI PA.. 0.00 % 0.00 %

+2.00 (+0.18%)

N/A
ESIH:LSE iShares MSCI Europe Healt.. 0.00 % 0.00 %

+0.05 (+0.18%)

USD 0.83B
ESIS:F Ishares VI PLC - Ishares .. 0.00 % 0.00 %

+0.03 (+0.18%)

N/A
ESIS:XETRA iShares MSCI Europe Consu.. 0.00 % 0.00 %

+0.04 (+0.18%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.24% 64% D 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.24% 64% D 77% C+
Trailing 12 Months  
Capital Gain 19.38% 86% B+ 85% B
Dividend Return 0.61% 17% F 10% F
Total Return 19.99% 86% B+ 83% B
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 9.24% 64% D 62% D
Dividend Return 9.84% 57% F 58% F
Total Return 0.60% 33% F 14% F
Risk Return Profile  
Volatility (Standard Deviation) 12.45% 93% A 73% C
Risk Adjusted Return 79.06% 93% A 85% B
Market Capitalization 46.89B 78% C+ 95% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector